HYBRIDIZE THERAPEUTICS
Hybridize’s overarching goal is to help patients overcome untreatable viral diseases.
HYBRIDIZE THERAPEUTICS
Social Links:
Industry:
Biotechnology Health Care
Founded:
2019-01-01
Address:
Leiden, Zuid-Holland, The Netherlands
Country:
The Netherlands
Website Url:
http://www.hybridizetherapeutics.com
Total Employee:
1+
Status:
Active
Contact:
+31-617524713
Email Addresses:
[email protected]
Technology used in webpage:
Google Maps Google Maps API Google Maps For Work
Current Advisors List
Current Employees Featured
Official Site Inspections
http://www.hybridizetherapeutics.com
- Host name: 66.8.205.92.host.secureserver.net
- IP address: 92.205.8.66
- Location: Germany
- Latitude: 51.4476
- Longitude: 7.0122
- Timezone: Europe/Berlin
More informations about "Hybridize Therapeutics"
Hybridize Therapeutics - Crunchbase Company Profile …
Hybridize’s overarching goal is to help patients overcome untreatable viral diseases. RNA-based therapies designed to protect kidneys by targeting specific kidney cells, aiming to treat acute and chronic kidney diseases.See details»
Press room - Hybridize Therapeutics
In September 2019, Eric founded Hybridize Therapeutics in the Leiden Bioscience Park, a setting that had proven to be fertile soil for numerous RNA therapeutic companies.See details»
Hybridize Therapeutics - LinkedIn
Hybridize's mission is to help patients overcome untreated kidney diseases. We do this by developing RNA-based therapies. Currently, we are nearing Phase 1 clinical trials (together with our partner AiCuris Anti-Infectives) for our therapy …See details»
Overview, News & Similar companies - ZoomInfo.com
Feb 9, 2022 View Hybridize Therapeutics (www.hybridizetherapeutics.com) location in South Holland, Netherlands , revenue, industry and description. Find related and similar companies …See details»
Hybridize Therapeutics - Leiden, Netherlands - bionity.com
Feb 14, 2022 hybridizetherapeutics.com. Contact. Profile News. Contact. About Hybridize Therapeutics. Hybridize Therapeutics is a spin-off from the Department of Nephrology at the …See details»
AiCuris and Hybridize Therapeutics enter worldwide license …
Feb 9, 2022 AiCuris acquires exclusive rights to develop and commercialize Hybridize’s program to prevent severe disease from BK virus (BKV) infections in immunocompromised patients …See details»
Hybridize Therapeutics - VentureRadar
"Hybridize Therapeutics (2019) is a biotech spin-off out of the Leiden University Medical Center with a rich history in research & development in RNA-based therapies. Hybridize’s overarching …See details»
Company Information - RocketReach
Hybridizetherapeutics.com; 1 3164224XXXX; Eric van der Veer Chief Scientific Officer, Chief Executive Officer at Hybridize Therapeutics The Hague, South Holland, Netherlands View. 2 …See details»
Hybridize Therapeutics (NL) - life-sciences-europe.com
Sep 1, 2019 Upcoming Events. Medtech Congress 2024 Courroux (CH) BioCentury-BayHelix China Healthcare Summit 2024 Shanghai; Lab Innovations 2024 Birmingham; BIO-Europe …See details»
Hybridize Therapeutics - Products, Competitors, Financials, …
Hybridize Therapeutics focuses on developing RNA-based therapies for kidney diseases within the biopharmaceutical industry. Use the CB Insights Platform to explore Hybridize …See details»
Hybridize Therapeutics - PitchBook
Hybridize Therapeutics General Information Description. Developer of an RNA-based therapy technology intended for patients with acute and chronic kidney diseases. The company's …See details»
Hybridize Therapeutics: Drug pipelines, Patents, Clinical trials
Jul 5, 2023 Explore Hybridize Therapeutics with its drug pipeline, therapeutic area, technology platform, 2 news, Disease Domain:Infectious Diseases, Technology Platform:Unknown, …See details»
Hybridize Therapeutics - Leiden Bio Science Park
Housing over 215 organisations, including 150 Life Sciences & Health (LSH) companies – from start-ups to multinationals – and several internationally acclaimed research institutes, the …See details»
AiCuris and Hybridize Therapeutics Enter Worldwide License …
Feb 9, 2022 For more information, please visit www.hybridizetherapeutics.com. Contacts: Media Relations. AiCuris Anti-infective Cures AG MC Services AG Katja Woestenhemke Dr. Solveigh …See details»
Hybridize Therapeutics - Mibiton
Hybridize Therapeutics is developing RNA therapeutics to treat kidney diseases. Current focus areas are the BK virus- and fibrosis programs. The BK-virus program aims to develop an …See details»
Interview Hybridize - Health Holland
Van der Veer also needed a different mindset and a team. Looking back, he is very glad someone told him about the Venture Challenge. ‘Before participating, I thought about what the …See details»
Hybridize: Developing RNA Platform for Antiviral Therapies
Eric van der Veer, CSO and co-founder of the Leiden University Medical Center spin-off Hybridize Therapeutics B.V., is developing a platform technology for the treatment of BK virus-mediated …See details»
Hybridize | Lifesciences @ Work
N a yearly basis, more than 80,000 patients worldwide suffering from end-stage renal disease obtain a lease-on-life by receiving a donated kidney, dramatically improving their quality of life. …See details»
Hybridize Therapeutics (Hybridize Therapeutics) - 药物管线_专利_ …
了解Hybridize Therapeutics (Hybridize Therapeutics)公司的药物管线，治疗领域，技术平台，以及它的2篇新闻，疾病领域:感染，技术平台:反义寡核苷酸，未知，反义肽核酸，药物:HYB …See details»